- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01612975
The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
The Effect of Perioperative Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study the investigators will attempt to reduce the degree of inflammation (and thus polymorphonuclear leukocyte counts) in the pleural space following a lung resection procedure by administering the Non Steroid Anti-Inflammatory Drug (NSAID) Naproxen in tandem with Proton Pump Inhibitor (PPI) Pantoprazole, ideally leading towards a significantly reduced volume of transudate and exudate generated.
This will be achieved by running a placebo-controlled double blinded randomized control trial where investigators and participants will be blinded so as to eliminate experimenter bias. After screening for suitable participants using stringent inclusion and exclusion criteria, patients will be administered by allied health professionals 500mg Naproxen twice daily and 40mg Pantoprazole once daily, or an identical placebo for four weeks following resection surgery. Patients will undergo a thorough examination during their scheduled follow-up appointments to monitor general vitals as well as possible gastrointestinal complications. The primary outcome is a significant reduction (Δ100ml) of chest fluid extracted in the intervention arm of the study in comparison to that of the control arm. Secondary outcomes will include a reduction in length of stay measured in days between control and intervention arms as well as a reduction in the total number of days chest tubes are retained in-situ. Conditions such as mortality and morbidity, the onset of complications, and general re-admission rates will also be recorded.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare Hamilton
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be 18 years of age or older
- Participants must be undergoing a major lung resection due to primary or secondary malignancy
- Must have an aptitude for following directions and commitment to the study
Exclusion Criteria:
- Patients who are unable to read and communicate in English
- Patients undergoing a pneumonectomy or Open lung resection
- Previous treatments on the same anatomical side including chemotherapy, radiation therapy, and radio-frequency ablation
- Patients who have undergone decortication for empyema or malignancy.
- Patients who have a chest tube in-situ for persistent air leak
- Patients with clinical or laboratory indicators of renal failure, defined as serum creatinine level of 170µmol/l
- Patients with active or previous history of peptic ulcer disease
- Patients with a known intolerance to Proton Pump Inhibitors (PPIs)
- Known allergy to study drugs
- Use of NSAIDs 4 weeks prior to randomization or on-going use of NSAIDs.
- The use of any medications known to reduce inflammation, including but not limited to: steroids (both oral and intravenously), methotrexate, COX-II inhibitors, other NSAIDs
- Chest tube for persistent air leak.
- Patients who are pregnant or lactating
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Inability or unwillingness of individual or legal guardian/representative to give written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants.
Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it.
Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo).
Participants will not know which arm of the study they belong to.
In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
|
Inert, inactive placebo pill similar in appearance to naproxen allocation.
To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
|
EXPERIMENTAL: Naproxen
Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem.
Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring.
Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery.
They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
|
Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem.
Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring.
Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery.
They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in volume of pleural effusion collected
Time Frame: 4 weeks
|
The investigators are looking to measure the volume of pleural effusion collected from in-situ chest tubes in patients following a lung resection, measured in mL
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital length of stay; compared between intervention and control arms
Time Frame: 4 weeks
|
The length of stay will be measured from the admitting day to the day of discharge to home.
|
4 weeks
|
Gastrointestinal complications
Time Frame: 4 weeks
|
Recorded as a binary event, adverse events related to the gastrointestinal tract may occur in participants undergoing treatment.
The extent of this occurrence will determine whether or not further intervention by the Data and Safety Monitoring Committee is necessary.
|
4 weeks
|
General re-admission rates
Time Frame: 4 weeks
|
Participants recently discharged following a lung resection have a chance to be re-admitted for a post-operative complication.
This will be measured as a binary event and the total associated length of stay associated with the episode.
|
4 weeks
|
Total number of days chest tubes remain in-situ
Time Frame: 4 weeks
|
This outcome is related to the volume of pleural effusion produced and will measure the time chest tubes remain in place following surgery, measured in days.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yaron Shargall, MD, BSc, FRCSC, McMaster University
Publications and helpful links
General Publications
- Watanabe A, Watanabe T, Ohsawa H, Mawatari T, Ichimiya Y, Takahashi N, Sato H, Abe T. Avoiding chest tube placement after video-assisted thoracoscopic wedge resection of the lung. Eur J Cardiothorac Surg. 2004 May;25(5):872-6. doi: 10.1016/j.ejcts.2004.01.041.
- Cerfolio RJ, Bryant AS. Results of a prospective algorithm to remove chest tubes after pulmonary resection with high output. J Thorac Cardiovasc Surg. 2008 Feb;135(2):269-73. doi: 10.1016/j.jtcvs.2007.08.066.
- Suemitsu R, Ondo K, Fukuyama S, Ueda H. Late-period-onset chylothorax after a pulmonary resection for lung cancer: a case report. Ann Thorac Cardiovasc Surg. 2007 Oct;13(5):345-8.
- Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J. 1997 Oct;10(10):2411-8. doi: 10.1183/09031936.97.10102411.
- Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009.
- Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.
- Ackerman N, Tomolonis A, Miram L, Kheifets J, Martinez S, Carter A. Three day pleural inflammation: a new model to detect drug effects on macrophage accumulation. J Pharmacol Exp Ther. 1980 Dec;215(3):588-95.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Neoplasms by Site
- Pleural Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Pleural Neoplasms
- Pleural Effusion, Malignant
- Pleural Effusion
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Naproxen
Other Study ID Numbers
- SJHHNaproxenRCT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pleural Effusion
-
Naestved HospitalTerminatedMalignant Pleural Effusion | Exudative Pleural EffusionDenmark
-
Oregon Health and Science UniversityThe Gerber FoundationCompletedChylous Pleural Effusion Following Cardiothoracic SurgeryUnited States
-
Sheng HuWuhan Binhui Biotechnology Co., Ltd.RecruitingMalignant Pleural Effusion | Malignant Peritoneal EffusionChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPleural NeoplasmUnited States
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
JemincareZhejiang Hangyu Pharmaceutical Co., LtdRecruitingMalignant Pleural EffusionChina
-
National University of Ireland, Galway, IrelandRecruitingMalignant Pleural EffusionIreland
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruiting
-
Washington University School of MedicineMerit Medical Systems, Inc.CompletedMalignant Pleural EffusionUnited States
-
Duke UniversityTerminated
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States